Fennec Pharmaceuticals Inc. (FENC) Financial Analysis & Valuation | Quarter Chart
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex T... more
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the cl... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $369.25M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jeffrey S. Hackman |
| IPO Date | 2017-09-15 | CAGR | 105.64% |
| Employees | 35 | Website | www.fennecpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
FENC chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $280.44M | P/E | -81.77 | Forward P/E | 10.93 | PEG | — |
| P/S | 0.48 | P/B | 0.68 | P/CF | -14.21 | P/FCF | -14.3 |
| Sales | $59.22M | Sales 1Y | 77.83% | Sales 3Y | 805.94% | Sales 5Y | 34735.88% |
| EPS | $-0.13 | EPS 1Y | -68.03% | EPS 3Y | -87.63% | EPS 5Y | -80.66% |
| Sales QoQ | 18.31% | EPS QoQ | 792.86% | Sales QoQ Avg | 16.91% | EPS QoQ Avg | 312.75% |
| Gross Margin | 93.73% | Operating Margin | -1.96% | Profit Margin | -5.49% | ROCE | -1.84% |
| ROA | -4% | ROE | -12% | Altman Z Score | 4.08 | Piotroski Score | 5 |
| Current Ratio | 5.85 | Quick Ratio | 5.66 | Cash Ratio | 3.33 | Op. CF Ratio | 0 |
| Debt/Equity | — | Debt/Assets | — | Lt Debt/Equity | — | Lt Debt/Cap. | — |
| Intrst Cov. | -1.29 | Inventory Turnover | 1.56 | Asset Turnover | 0.78 | Receivables Turnover | 2.55 |
| Enterprise Value | $280.44M | P/E Ratio | -81.77 |
| Forward P/E | 10.93 | PEG Ratio | — |
| P/S Ratio | 0.48 | P/B Ratio | 0.68 |
| P/CF Ratio | -14.21 | P/FCF Ratio | -14.3 |
| EPS | $-0.13 | EPS Growth 1Y | -68.03% |
| EPS Growth 3Y | -87.63% | EPS Growth 5Y | -80.66% |
| Revenue Growth 1Y | 77.83% | Gross Margin | 93.73% |
| Operating Margin | -1.96% | Profit Margin | -5.49% |
| ROE | -12% | ROA | -4% |
| ROCE | -1.84% | Current Ratio | 5.85 |
| Quick Ratio | 5.66 | Cash Ratio | 3.33 |
| Debt/Equity | — | Interest Coverage | -1.29 |
| Altman Z Score | 4.08 | Piotroski Score | 5 |
Fennec Pharmaceuticals Inc. (FENC) valuation & financials
Fennec Pharmaceuticals Inc. (FENC) has a market capitalization of $369.25M and trades at a price-to-earnings ratio of -81.8. It operates in the Healthcare sector (Biotechnology).
Fennec Pharmaceuticals Inc.'s revenue grew +77.8% over the last year.
Fennec Pharmaceuticals Inc.'s next earnings report is scheduled for November 12, 2026 before market open (provider scheduled date); analysts estimate EPS of $0.09. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)